Results 221 to 230 of about 173,532 (309)

Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof-of-Concept Study. [PDF]

ChemMedChem
Lowe S, Satikuvar V, Syeda TM, Cal M, Mäser P, Kaiser M, Kadri H.   +6 more
europepmc   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Targeting <i>Plasmodium falciparum</i> with purine antimetabolites as a therapeutic strategy. [PDF]

Front Microbiol
Tashie W, de Koning HP, Duah-Quashie NO, Quashie NB.   +3 more
europepmc   +1 more source

Loss of DNA methylation is not associated with venetoclax–hypomethylating agents synergy in acute myeloid leukaemia cells

British Journal of Haematology, EarlyView.
Aida Selimović‐Pašić, Lisa Haglund, Maike Bensberg, Júlia Goldmann, Padraig D'arcy, Sandra Hellberg, Colm E. Nestor   +6 more
wiley   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]

Case Rep Infect Dis
Tchiakpe E, Diop-Ndiaye H, Osawe S, Toure-Kane C, Yessoufou A.   +4 more
europepmc   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Recent Advances in Searching for DNMT Inhibitors and Their Potential Application in Treating Human Diseases. [PDF]

Int J Mol Sci
Bulygin AA, Davletgildeeva AT, Kuznetsov NA.   +2 more
europepmc   +1 more source

Prior PrEP use and discontinuation in individuals newly diagnosed with HIV

HIV Medicine, EarlyView.
Abstract Background In settings with high uptake of HIV pre‐exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
Rohan Saini, Sarah Fidler, Marta Boffito, Vicky Tittle, Nicolo Girometti, Gary Whitlock, on behalf of the Dean Street Collaborative Group, Keerti Gedela, Franki Lander, Alan McOwan, Diarmuid Nugent, Sheel Patel, Sashini Payagala, Tara Suchak, Vicky Tittle, Gary Whitlock   +15 more
wiley   +1 more source

The long march towards testing the adenosine receptor agonism hypothesis for human cerebroprotection: The story of the A₁R/A₃R receptor agonist AST-004. [PDF]

Purinergic Signal
Liston TE, Korinek WS, Jacobson KA, Lechleiter JD.   +3 more
europepmc   +1 more source